Table 2: Concomitant medications in patients with type 2 diabetes and microalbuminuria at baseline and during follow-up according to treatment with ACE inhibitors YES or NO or with ndCCB YES or NO.

BaselineFollow-up
ACEi YesACEi NondCCB YesndCCB NoACEi YesACEi NondCCB YesndCCB No
Number of patients 42 48 50 40 39 44 47 36

Concomitant medicationnumber (percent)number (percent)

Glucose-lowering regimen
 Diet alone5 (11.9)12 (25.0)12 (24.0)5 (12.5)4 (10.3)8 (18.2)8 (17.0)4 (11.1)
 Oral hypoglycemic agent  alone29 (69.0)21 (43.8)26 (52.0)24 (60.0)24 (61.5)21 (47.7)26 (55.3)19 (52.8)
 Insulin and oral  hypoglycemic agent5 (11.9)12 (25.0)10 (20.0)7 (17.5)11 (28.2)16 (36.4)13 (27.7)14 (38.9)
 Insulin alone3 (7.1)3 (6.3)2 (4.0)4 (10.0)3 (7.7)3 (6.8)3 (6.4)3 (8.3)

Antihypertensive agents
 Any22 (52.4)26 (54.2)23 (46.0)25 (62.5)32 (82.1)38 (86.4)37 (78.7)33 (91.7)
 Diuretic5 (11.9)11 (22.9)9 (18.0)7 (17.5)10 (25.6)14 (31.8)16 (34.0)8 (22.2)
 Beta-blocker6 (14.3)2 (4.2)3 (6.0)5 (12.5)4 (10.3)3 (6.8)4 (8.5)3 (8.3)
 Calcium-channel  blocker (dihydropyridine) 11 (26.2)15 (31.3)12 (24.0)14 (35.0)14 (35.9)16 (36.4)14 (29.8)16 (44.4)
 Sympatholytic agent7 (16.7)8 (16.7)9 (18.0)6 (15.0)28 (71.8)32 (72.7)29 (61.7)31 (86.1)

Lipid-lowering agents
 Any3 (7.1)3 (6.3)1 (2.0)5 (12.5)6 (15.4)9 (20.5)6 (12.8)9 (25.0)
 Statin alone01 (2.1)01 (2.5)2 (5.1)7 (15.9)4 (8.5)5 (13.9)
 Fibrate alone3 (7.1)1 (2.1)04 (10.0)*2 (5.1)01 (2.1)1 (2.8)
 Statin and fibrate00002 (5.1)1 (2.3)03 (8.3)

Antiplatelet agent1 (2.4)01 (2.0)06 (15.4)3 (6.8)6 (12.8)3 (8.3)

* P<.05 versus ndCCB YES.